intrasplen
inject
human
peripher
blood
mononuclear
cell
pbmc
sever
immun
defici
nodscid
mice
caus
massiv
transient
domin
expans
human
b
cell
spleen
permit
easi
isol
human
monoclon
antibodi
specif
differ
antigen
kohler
milsteinbas
method
studi
human
hivspecif
antibodi
respons
circul
mice
intrasplen
transfer
pbmc
untreat
hivinfect
patient
detect
high
viral
load
well
haarttreat
untreat
patient
kept
undetect
viral
load
latter
refer
natur
suppressor
excel
b
cell
expans
obtain
pbmc
high
level
replic
viru
observ
transfer
pbmc
untreat
virem
patient
strong
multispecif
hivspecif
antibodi
respons
observ
transfer
pbmc
untreat
virem
patient
natur
suppressor
contrast
weak
paucispecif
antibodi
respons
detect
mice
reconstitut
pbmc
success
treat
patient
base
observ
conclud
use
intraspleen
mous
model
confirm
presenc
hivspecif
circul
memori
b
cell
untreat
patient
natur
suppressor
b
nearli
complet
absenc
circul
memori
b
cell
patient
receiv
highli
activ
antiretrovir
therapi
use
intraspleen
model
gener
larg
number
immort
b
cell
isol
two
human
monoclon
antibodi
conclud
intraspleen
hupbl
nodscid
model
small
anim
model
use
analysi
antibodi
respons
hiv
found
patient
abbrevi
haart
highli
activ
antiretrovir
therapi
hcv
hepat
c
viru
hiv
human
immunodefici
viru
hupbl
human
peripher
blood
lymphocyt
nodscid
nonobes
diabeticsever
combin
immunodefici
pbmc
periphar
blood
mononuclear
cell
correspond
author
immun
defici
mice
human
cell
surviv
function
valuabl
tool
vivo
studi
human
immun
function
human
diseas
includ
autoimmun
disord
lymphoma
infecti
diseas
murphi
et
al
studi
hiv
pathogenesi
therapi
two
commonli
use
system
scidhu
model
hupblscid
model
mccune
et
al
mosier
et
al
borkow
latter
model
peripher
blood
mononuclear
cell
pbmc
commonli
inject
peritoneum
sever
immun
defici
mice
result
human
cell
graft
cell
predomin
describ
variant
hupbl
nod
scid
model
pbmc
transfer
spleen
instead
peritoneum
depraeter
et
al
brief
intraspleen
transfer
result
massiv
nonspecif
celldepend
expans
b
cell
activ
secret
immunoglobulin
blood
mice
antigen
specif
mous
sera
reflect
specif
found
human
b
cell
donor
elicit
infect
immun
six
ten
day
post
inject
human
b
cell
transient
predomin
mous
spleen
easili
recov
subsequ
immort
procedur
gener
human
monoclon
antibodi
far
success
gener
human
monoclon
antibodi
hepat
b
surfac
core
antigen
cao
et
al
vanlandschoot
et
al
hepat
c
depraeter
et
al
tetanu
toxoid
unpublish
result
envisag
hupbl
nodscid
model
may
use
isol
therapeut
human
antibodi
analys
antibodi
repertoir
immun
vaccin
individu
help
design
vaccin
virus
like
hcv
hiv
analyt
vaccinolog
present
studi
assess
whether
transfer
pbmc
infect
patient
would
result
good
b
cell
expans
circul
hivspecif
antibodi
allow
gener
monoclon
hivspecif
antibodi
success
necessarili
guarante
sinc
hiv
infect
affect
number
function
b
lymphocyt
lymphocyt
drive
expans
b
cell
transfer
pbmc
mice
depraeter
et
al
howev
hiv
infect
known
caus
rapid
deplet
human
cell
scid
mice
mosier
et
al
b
cell
behaviour
alter
repres
paradox
polyclon
activ
b
cell
lane
et
al
result
increas
frequenc
circul
antibodi
secret
cell
hypergammaglobulinemia
yarchoan
et
al
martinezmaza
et
al
amadori
et
al
amadori
et
al
shirai
et
al
untreat
haarttreat
chronic
hiv
infect
memori
b
cell
gradual
disappear
circul
de
milito
et
al
fonder
et
al
chong
et
al
titanji
et
al
deregul
express
sever
surfac
molecul
indraccolo
et
al
samuelsson
et
al
moir
et
al
moir
et
al
decreas
respons
b
cell
activ
vivo
vitro
describ
lane
et
al
cong
et
al
inform
consent
obtain
particip
studi
protocol
approv
ethic
committe
ghent
univers
hospit
belgium
project
number
institut
tropic
medicin
refer
number
edta
anticoagul
blood
drawn
infect
patient
attend
hiv
outpati
clinic
either
ghent
univers
hospit
cv
institut
tropic
medicin
vi
plasma
kept
frozen
use
pbmc
prepar
ficollhypaqu
centrifug
densiti
gml
nycom
pharma
store
liquid
nitrogen
aliquot
pbmc
use
produc
chimer
mice
nodltszprkdc
scid
prkdc
scid
nodscid
mice
sever
immun
defici
sinc
lack
function
b
cell
display
reduc
innat
immun
haemolyt
complement
shultz
et
al
mice
bred
maintain
specif
pathogenfre
condit
mice
hous
individu
ventil
cage
fed
autoclav
food
water
mice
use
eight
twelv
week
age
studi
approv
anim
ethic
committe
faculti
medicin
univers
ghent
belgium
ecp
gener
chimer
anim
nodscid
mice
condit
inject
mg
rat
monoclon
antibodi
direct
murin
receptor
tanaka
et
al
tanaka
et
al
total
bodi
gamma
irradi
gy
gener
linear
acceler
twentyfour
hour
later
pbmc
infect
patient
inject
fusion
experi
cell
inject
pbmc
patient
inject
three
mice
total
human
igg
concentr
determin
mous
plasma
use
inhous
elisa
describ
previous
tournoy
et
al
hivspecif
antibodi
profil
determin
human
mous
plasma
use
innolia
hiv
confirm
strip
innogenet
strip
coat
differ
antigen
antibodi
antigen
detect
develop
line
score
accord
manufactur
instruct
sampl
dilut
accord
manufactur
instruct
hybridoma
supernat
screen
hivspecif
antibodi
use
ortho
abcaptur
elisa
test
system
viral
load
measur
use
coba
amplicor
version
roch
accord
manufactur
instruct
limit
detect
human
sampl
log
geqml
mous
sampl
log
geqml
mous
sampl
dilut
due
limit
sampl
volum
avail
spleen
cell
reconstitut
nodscid
mice
heteromyeloma
cell
wash
calciumfre
phosphat
buffer
salin
pb
mix
ratio
fifti
percent
polyethylen
glycol
peg
boehring
mannheim
ad
min
wash
away
fuse
cell
cultur
medium
supplement
human
recombin
insulin
boerhing
mannheim
fetal
clone
serum
hyclon
bm
condim
boerhing
mannheim
irradi
pbmc
healthi
seroneg
donor
ad
feeder
cell
fusion
medium
contain
hypoxanthineaminopterinthymidin
hat
life
technolog
ouabain
sigma
ad
day
fusion
heteromyeloma
cell
line
hat
sensit
ouabain
resist
cultur
replenish
fresh
medium
everi
three
day
statist
perform
use
mannwitney
utest
kruskalw
test
medcalc
program
version
schoonjan
et
al
pbmc
isol
blood
infect
patient
divid
three
group
accord
treatment
statu
viral
burden
plasma
tabl
group
consist
six
individu
receiv
haart
least
six
month
whose
plasma
viral
load
rang
log
geqml
second
group
group
b
consist
six
subject
current
receiv
haart
kept
viral
load
limit
detect
b
log
geqml
third
group
group
c
consist
three
subject
receiv
antivir
agent
natur
control
viral
replic
limit
detect
b
log
geq
ml
longitudin
detail
viral
load
count
three
natur
suppressor
shown
fig
approxim
pbmc
use
reconstitut
optim
condit
nodscid
mice
direct
inject
spleen
two
mice
die
day
transfer
thirti
mice
surviv
day
transfer
seven
one
week
thereaft
death
mice
due
sever
graftversushost
diseas
easili
diagnos
presenc
hunch
back
ruffl
fur
emaci
loos
stool
excel
expans
b
cell
achiev
mice
demonstr
increas
human
igg
level
blood
tabl
averag
igg
level
group
mean
sem
one
week
inject
two
week
inject
group
b
level
one
week
two
week
group
c
averag
human
igg
level
one
week
two
week
polyclon
human
igg
level
differ
significantli
group
p
n
group
subject
receiv
antiretrovir
therapi
viral
load
limit
detect
group
b
subject
receiv
highli
activ
antiretrovir
therapi
haart
suppress
viral
replic
limit
detect
group
c
subject
suppress
viral
replic
limit
detect
without
receiv
antiretrovir
therapi
data
present
mean
standard
error
mean
sem
statist
signific
differ
p
b
versu
group
earli
day
reconstitut
high
viral
genom
concentr
measur
blood
mice
reconstitut
pbmc
untreat
virem
hiv
patient
group
level
increas
one
week
later
tabl
contrast
viral
replic
weak
absent
blood
mice
reconstitut
pbmc
treat
patient
natur
suppressor
group
b
group
c
differ
viral
replic
group
log
geqml
one
week
log
geqml
two
week
group
b
b
log
geq
ml
one
week
log
geqml
two
week
group
group
c
b
log
geqml
one
week
b
log
geqml
two
week
highli
signific
p
b
correl
viral
burden
mous
plasma
human
igg
level
mous
plasma
p
n
shown
fig
hivspecif
antibodi
profil
strong
broadli
reactiv
pbmc
untreat
virem
patient
group
natur
suppressor
group
c
use
howev
hivspecif
reactiv
weak
absent
paucispecif
pbmc
patient
receiv
antivir
therapi
group
b
kruskalw
analysi
show
statist
signific
differ
plevel
antigen
two
week
post
transfer
untreat
patient
group
hivspecif
antibodi
respons
envelop
direct
natur
suppressor
group
c
respons
gagdirect
contrast
antibodi
profil
induc
transfer
pbmc
mice
hivspecif
antibodi
respons
human
plasma
differ
group
p
n
tabl
stabl
hybridoma
produc
human
monoclon
antibodi
hiv
gag
protein
gener
twice
pbmc
untreat
hivinfect
subject
whose
viral
load
low
log
geqml
whose
plasma
antibodi
show
broadli
neutral
activ
steyaert
et
al
press
activ
human
b
cell
recov
mous
spleen
one
week
inject
previou
experi
show
time
human
b
cell
predominantli
present
spleen
human
b
cell
experi
fuse
heteromyeloma
cell
line
extens
dilut
seed
well
frequenc
b
cell
per
well
day
cluster
viabl
cell
detect
seed
well
although
igg
secret
detect
hivspecif
antibodi
found
one
cell
success
subclon
monoclon
obtain
second
experi
ii
seed
b
cell
done
vari
number
well
seed
b
cell
per
well
b
cell
per
well
b
cell
per
well
b
cell
per
well
well
seed
highest
densiti
b
cell
per
well
cluster
immort
b
cell
obtain
hivspecif
antibodi
present
respect
howev
antihiv
posit
decreas
rapidli
limit
dilut
step
unsuccess
well
seed
lowest
concentr
b
cell
per
well
viabl
cell
cluster
present
well
respect
antihiv
antibodi
well
respect
strike
loss
antihiv
posit
observ
well
seed
b
cell
per
well
one
stabl
hybridoma
cell
line
produc
could
gener
report
describ
explor
hupbl
nodscid
model
depraeter
et
al
transfer
pbmc
hivinfect
patient
engraft
transfer
excel
mice
function
engraft
human
b
cell
demonstr
earli
vigor
antibodi
respons
blood
mice
transfer
pbmc
untreat
hivinfect
patient
detect
viremia
optim
condit
nodscid
mice
result
replic
endogen
viru
mice
reconstitut
pbmc
patient
undetect
viral
load
replic
often
remain
detect
b
log
geqml
assum
provir
load
transfer
pbmc
strongli
relat
viral
load
plasma
patient
andreoni
et
al
ngogianghuong
et
al
hivspecif
antibodi
respons
transfer
pbmc
form
untreat
virem
patient
natur
suppressor
strong
multispecif
hivspecif
antibodi
respons
weak
paucispecif
transfer
pbmc
patient
receiv
haart
sinc
human
circul
memori
b
cell
constitut
basi
antibodi
present
blood
mice
conclud
treat
hivinfect
patient
lost
hivspecif
memori
b
cell
circul
gradual
loss
circul
memori
b
cell
chronic
hiv
infect
occur
titanji
et
al
inde
report
memori
specif
b
cell
disappear
blood
month
success
antiretrovir
therapi
fonder
et
al
also
note
hivspecif
antibodi
profil
transfer
pbmc
untreat
virem
patient
differ
hivspecif
antibodi
profil
obtain
transfer
pbmc
natur
suppressor
latter
group
antibodi
respons
mainli
direct
protein
encod
gag
gene
respons
pbmc
virem
subject
mainli
direct
viral
envelop
antibodi
env
gag
antigen
mount
hiv
infect
differ
extent
sustain
throughout
cours
hiv
infect
antienv
usual
present
high
titr
even
individu
progress
diseas
antigag
respons
lost
diseas
progress
schmidt
et
al
cheingsongpopov
et
al
zwart
et
al
hogervorst
et
al
strathde
et
al
binley
et
al
declin
antigag
thought
surrog
marker
loss
cell
help
binley
et
al
trkola
et
al
therefor
like
gagdirect
antibodi
untreat
natur
control
patient
reflect
good
function
cell
help
hiv
antibodi
profil
differ
group
intrasplen
expand
pbmc
diverg
howev
present
correspond
human
plasma
like
result
compartment
mous
model
antibodi
product
deriv
memori
b
cell
present
circul
hivinfect
subject
contrast
hivspecif
antibodi
detect
human
plasma
predominantli
deriv
plasma
cell
bone
marrow
antibodi
produc
cell
lymph
node
morri
et
al
antibodi
also
secret
extend
period
time
order
isol
hivspecif
monoclon
antibodi
use
hupbl
nodscid
model
clear
pbmc
untreat
patient
need
use
patient
hivspecif
memori
b
cell
peripher
blood
abl
gener
larg
number
igg
produc
hybridoma
cell
isol
monoclon
hybridoma
cell
line
limit
dilut
difficult
sever
possibl
explan
low
success
rate
first
untreat
hiv
patient
reduc
number
memori
b
cell
secondli
estim
untreat
patient
memori
b
cell
hivspecif
fonder
et
al
previous
show
day
inject
pbmc
human
b
cell
present
spleen
depraeter
et
al
would
suggest
hivspecif
b
cell
avail
immort
final
notic
immort
b
cell
grew
slowli
antihiv
product
easili
lost
clearli
b
cell
function
respons
deregul
hiv
infect
appar
hiv
also
affect
immort
b
cell
slow
growth
fuse
b
cell
loss
hivspecif
antibodi
product
also
observ
author
buchach
et
al
hypothes
genom
instabl
cell
within
first
week
immort
respons
problem
nevertheless
abl
isol
two
stabl
human
monoclon
cell
line
produc
antibodi
gag
protein
human
monoclon
antibodi
specif
mainli
use
diagnost
purpos
far
human
monoclon
antibodi
hiv
produc
immort
b
cell
ebv
gorni
et
al
fuse
b
cell
appropri
myeloma
cell
buchach
et
al
method
howev
low
effici
therefor
altern
strategi
develop
mous
model
pbmc
inject
directli
spleen
result
strong
polyclon
activ
strike
expans
b
cell
memori
b
cell
present
pbmc
mix
recent
memori
b
cell
use
success
gener
human
monoclon
antibodi
sar
coronaviru
cultur
presenc
ebvand
suitabl
growth
factor
traggiai
et
al
whether
approach
success
gener
human
monoclon
antibodi
hiv
remain
determin
conclus
transplant
human
lymphoid
cell
hivinfect
patient
spleen
immun
defici
nodscid
mice
feasibl
studi
hivspecif
human
humor
immun
respons
isol
human
monoclon
antibodi
hiv
intrasplen
transfer
might
also
use
increas
number
hivspecif
memori
b
cell
singlechain
phage
display
librari
construct
hupbl
nodscid
model
may
therefor
help
identifi
isol
monoclon
antibodi
bind
broadli
neutral
enhanc
nonneutr
epitop
hiv
antibodi
use
develop
candid
vaccin
